Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Waters

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Neurology|October 22, 1998
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study GroupA Lieberman, C W Olanow, K Sethi, et al.
Neurology|September 26, 1997
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study GroupC H Waters, M Kurth, P Bailey, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1993
Neuropathology of lubag (x-linked dystonia parkinsonism)C H Waters, P L Faust, J Powers, et al.
Neurosurgery|June 1, 1995
Ventroposterior medial pallidotomy in patients with advanced Parkinson's diseaseJ P Sutton, W Couldwell, M F Lew, et al.
Neurosurgery|May 1, 1990
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observationsM L Apuzzo, J H Neal, C H Waters, et al.
Neurology|August 1, 1993
Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two womenC H Waters, H Takahashi, K C Wilhelmsen, et al.
European Journal of Haematology|April 1, 1995
The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalitiesR Carmel, P S Gott, C H Waters, et al.
Parkinsonism & Related Disorders|March 15, 2001
The long-term safety and efficacy of pramipexole in advanced Parkinson's diseaseW J. Weiner, S A. Factor, J Jankovic, et al.
Neurology|April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ T Hutton, W C Koller, J E Ahlskog, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled studyJ T Hutton, L V Metman, T N Chase, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Neurology|October 22, 1998
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study GroupA Lieberman, C W Olanow, K Sethi, et al.
Neurology|September 26, 1997
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study GroupC H Waters, M Kurth, P Bailey, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1993
Neuropathology of lubag (x-linked dystonia parkinsonism)C H Waters, P L Faust, J Powers, et al.
Neurosurgery|June 1, 1995
Ventroposterior medial pallidotomy in patients with advanced Parkinson's diseaseJ P Sutton, W Couldwell, M F Lew, et al.
Neurosurgery|May 1, 1990
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observationsM L Apuzzo, J H Neal, C H Waters, et al.
Neurology|August 1, 1993
Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two womenC H Waters, H Takahashi, K C Wilhelmsen, et al.
European Journal of Haematology|April 1, 1995
The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalitiesR Carmel, P S Gott, C H Waters, et al.
Parkinsonism & Related Disorders|March 15, 2001
The long-term safety and efficacy of pramipexole in advanced Parkinson's diseaseW J. Weiner, S A. Factor, J Jankovic, et al.
Neurology|April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ T Hutton, W C Koller, J E Ahlskog, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled studyJ T Hutton, L V Metman, T N Chase, et al.
Pageof 4